Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04538859

A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

Bronchiectasis is associated with repeated exacerbations which occurs at rates of 1.5-6.5 per patients per year, and are associated with an increased risk of admission and readmission to hospital, and high health care costs. In a local study carried out more than 10 years ago, idiopathic disease dominates and patients with bronchiectasis are mainly female with high hospitalization and mortality rates; 21.9 cases per 100,000 and 2.7 cases per 100,000 respectively. Moreover, exacerbation characterized by increases in symptoms requiring antibiotic treatment is associated with disease progression and significant mortality. Updated prevalence of this disease with the characteristics of etiology, clinical presentation and outcomes are needed to guide further management plan.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Bronchiectasis Adult

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chinese University of Hong

Hong Kong, Please Select

Location status: Recruiting

Location contact

Susanna SS Ng, MBChB

CONTACT

[email protected]

(852) 35053493

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 years or older
  • Clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of exacerbation, no requirement for supplemental antibiotic therapy)
  • Diagnosis of bronchiectasis defined by high-resolution computed tomography scan

Exclusion criteria

  • History of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary aspergilosis
  • Those who are unable to give consent

Treatment and study plan

Primary outcomes

  1. Number of bronchiectasis exacerbation

    Time frame: 5 years

Secondary outcomes

  1. Mortality rate

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Important dates

Study start
2020
Primary completion
2027
Study completion
2027
First posted
Sep 4, 2020
Registry last updated
Sep 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.